| Catalog No. | HS856086 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | VH-VH'-VH |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1, ALB, Albumin |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Purified by Nickel column. |
| Accession |
Q16552 & Q96PD4 & P02768 |
| Form |
Liquid |
| Storage buffer |
30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | Bispecific, Trivalent, M-1095, MSB-0010841, 1414386-05-2 |
|---|
| Background | Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
